Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Novartis says it plans to introduce the infant-friendly treatment on a largely not-for-profit basis in areas where malaria is endemic.
read more
AstraZeneca picked up the asset through its $1.3 billion acquisition of CinCor in January 2023.
read more
Ekterly's approval comes shortly after the drug got the nod from the U.S. FDA.
read more
The phase 3 trials will evaluate MK-8527, an investigational once-monthly, oral nucleoside reverse transcriptase translocation inhibitor for HIV pre-exposure prophylaxis.
read more
The cost-saving initiative will expand access to Contrave, Currax’s branded oral non-GLP-1 weight loss medication.
read more
Sanofi has finalized its deal to buy the rare disease specialist, picking up an approved drug for systemic mastocytosis.
read more
The Bristol Myers Squibb-Pfizer Alliance will offer a new direct-to-patient option for purchasing Eliquis.
read more
FDA commissioner Makary has tapped former biotech exec George Tidmarsh to lead one of the agency's largest divisions.
read more
Phase 2 data in hand, Alkermes will pursue “rapid initiation” of a phase 3 program for its OX2R agonist, alixorexton, in patients with narcolepsy type 1.
read more
Novartis will pay up to $1B for the rights to commercialize resulting oral covalent inhibitors in multiple inflammatory diseases.
read more
The review period for the once-daily, non-hormonal treatment, elinzanetant, will be extended for up to 90 days.
read more
The Johor plant is Colorcon’s 7th major film coating plant and its 16th manufacturing facility worldwide.
read more
Sephience is approved for the treatment of children and adults living with phenylketonuria, a rare metabolic disease that affects the brain.
read more
Madrigal has finalized a global license deal that could exceed $2B for a preclinical drug to treat MASH.
read more
Letters were sent to 17 pharma companies demanding they bring down prices of prescription drugs in the U.S. to match the lowest price offered in other developed nations.
read more